Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 677-683

  Kawashima, Hiroki ^a   Itoh, Akihiro ^a   Ohno, Eizaburo ^a   Nakamura, Masanao ^a   Miyahara, Ryoji ^b   Ohmiya, Naoki ^a   Hara, Kazuo ^c   Kanamori, Akira ^d   Itoh, Terutomo ^e   Taki, Tomoyuki ^f   Hirai, Takanori ^g   Hashimoto, Senju ^h   Takeda, Kinichi ⁱ   Goto, Hidemi ^a   Hirooka, Yoshiki ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d OGAKI MUNICIPAL HOSPITAL   (Japan)

^e JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^f Yamashita Hospital   (Japan)

^g KOMAKI CITY HOSPITAL   (Japan)

^h FUJITA HEALTH UNIVERSITY   (Japan)

ⁱ Nagoya Kyoritsu Hospital   (Japan)

Author keywords

Gemcitabine; Pancreatic cancer; Prospective study; S 1; Second line therapy

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INOPERABLE CANCER; KIDNEY FAILURE; LEUKOCYTE; LEUKOPENIA; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SPLEEN ABSCESS; THROMBOCYTE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ADULT; AGED; ALANINE TRANSAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; BILE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXONIC ACID; PANCREAS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT FAILURE;

EID: 80054693935     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1531-6     Document Type: Article

References (20)

1. Hirooka Y, Itoh A, Kawashima H, Ohno E, Ishikawa T, Matsubara H, Itoh Y, Nakamura M, Miyahara R, Ohmiya N, Niwa Y, Ishigami M, Katano Y, Goto H (2009) Diagnosis of pancreatic disorders using contrast-enhanced endoscopic ultrasonography and endoscopic elastography. Clin Gastroenterol Hepatol. (11 Suppl):S63-67
2. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D
3. D Cunningham I Chau DD Stocken JW Valle D Smith W Steward PG Harper J Dunn C Tudur-Smith J West S Falk A Crellin F Adab J Thompson P Leonard J Ostrowski M Eatock W Scheithauer R Herrmann JP Neoptolemos 2009 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 5487 5491 10.1200/JCO.2009.24.2446
4. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1986 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D
5. M Reni S Cordio C Milandri P Passoni E Bonetto C Oliani G Luppi R Nicoletti L Galli R Bordonaro A Passardi A Zerbi G Balzano L Aldrighetti C Staudacher E Villa V Di Carlo 2005 Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial Lancet Oncol 6 369 376 15925814 10.1016/S1470-2045(05)70175-3 1:CAS:528:DC%2BD2MXltFWktLw%3D
6. Y Hirooka A Itoh H Kawashima K Hara K Nonogaki T Kasugai E Ohno T Ishikawa H Matsubara M Ishigami Y Katano N Ohmiya Y Niwa K Yamamoto T Kaneko M Nieda K Yokokawa H Goto 2009 A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer Pancreas 38 e69 e74 19276867 10.1097/MPA.0b013e318197a9e3 1:CAS:528: DC%2BD1MXjsVyqtrg%3D
7. A Demols M Peeters M Polus R Marechal F Gay E Monsaert A Hendlisz JL Van Laethem 2006 Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 481 485 16434988 10.1038/sj.bjc.6602966 1:CAS:528:DC%2BD28Xhs1ers78%3D
8. N Tsavaris C Kosmas H Skopelitis P Gouveris P Kopterides D Loukeris F Sigala A Zorbala-Sypsa E Felekouras E Papalambros 2005 Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study Invest New Drugs 23 369 375 16012797 10.1007/s10637-005-1446-y 1:CAS:528:DC%2BD2MXmtVymtb4%3D
9. H Ulrich-Pur M Raderer G Verena Kornek B Schüll K Schmid K Haider W Kwasny D Depisch B Schneeweiss F Lang W Scheithauer 2003 Irinotecan plus raltitrexed vs. raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma Br J Cancer 88 1180 1184 12698181 10.1038/sj.bjc.6600883 1:CAS:528:DC%2BD3sXivFShs7w%3D
10. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H (2007) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol
11. C Morizane T Okusaka J Furuse H Ishii H Ueno M Ikeda K Nakachi M Najima T Ogura E Suzuki 2008 A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer Cancer Chemother Pharmacol 63 313 319 18398614 10.1007/s00280-008-0741-7
12. Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O (2010) Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. Epub ahead of print
13. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 2702835 10.1016/0197-2456(89)90015-9 1:STN:280:DyaL1M7ps1SjsQ%3D%3D
14. A Todaka A Fukutomi N Boku Y Onozawa S Hironaka H Yasui K Yamazaki K Taku N Machida T Sakamoto H Tomita 2010 S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure Jpn J Clin Oncol 40 567 572 20189975 10.1093/jjco/hyq005
15. Y Nakai H Isayama T Sasaki N Sasahira H Kogure K Hirano T Tsujino H Ijichi K Tateishi M Tada M Omata K Koike 2010 Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan Jpn J Clin Oncol 40 774 780 20462979 10.1093/jjco/hyq059
16. G Colucci R Labianca F Di Costanzo V Gebbia G Cartenì B Massidda E Dapretto L Manzione E Piazza M Sannicolò M Ciaparrone L Cavanna F Giuliani E Maiello A Testa P Pederzoli M Falconi C Gallo M Di Maio F Perrone Gruppo Oncologico Italia Meridionale (GOIM) Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD) Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 2010 Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study J Clin Oncol 28 1645 1651 20194854 10.1200/JCO.2009.25.4433 1:CAS:528:DC%2BC3cXmtVyhuro%3D
17. PA Philip J Benedetti CL Corless R Wong EM O'Reilly PJ Flynn KM Rowland JN Atkins BC Mirtsching SE Rivkin AA Khorana B Goldman CM Fenoglio-Preiser JL Abbruzzese CD Blanke 2010 Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 J Clin Oncol 28 3605 3610 20606093 10.1200/JCO.2009.25.7550 1:CAS:528:DC%2BC3cXhtFSksb3O
18. K Nakamura T Yamaguchi T Ishihara K Sudo H Kato H Saisho 2006 Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br J Cancer 94 1575 1579 16721372 1:CAS:528:DC%2BD28XltVOmurs%3D
19. MK Kim KH Lee BI Jang, et al. 2009 S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer Jpn J Clin Oncol 39 49 53 19060295 10.1093/jjco/hyn126
20. DY Oh Y Cha IS Choi SY Yoon IK Choi JH Kim SC Oh CD Kim JS Kim YJ Bang YH Kim 2009 A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer Cancer Chemother Pharmacol 65 527 536 19578850 10.1007/s00280-009-1059-9